FDA Inspection 1277270 — Surmasis Pharmaceutical, LLC

Surmasis Pharmaceutical, LLC — FEI 3011596846

The FDA completed an inspection of Surmasis Pharmaceutical, LLC on August 1, 2025 in Des Moines, IA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 4 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 1, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Des Moines, IA (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
229321 CFR 820.20(d)Quality plan
366921 CFR 820.20(c)Management review - defined interval, sufficient frequency
457621 CFR 211.192No written record of investigation